摘要
目的分析原发性肝癌诊断中使用异常凝血酶原Ⅱ+甲胎蛋白联合检测的价值。方法目的选取2021年1月—2022年10月青岛市第六人民医院收治的180例肝病患者为研究对象,其中原发性肝癌(Primary he-patic carcinoma,HCC)患者60例(HCC组),肝炎患者60例(肝炎组),肝硬化患者60例(肝硬化组),所有患者均行异常凝血酶原Ⅱ(Abnormal ProthrombinⅡ,PIVKA-Ⅱ)及甲胎蛋白(Alpha Fetoprotein,AFP)检测,对比3组的指标水平差异,分析AFP检验、PIVKA-Ⅱ以及联合检测的诊断效能。结果HCC组异常凝血酶原Ⅱ和甲胎蛋白高于其余两组,且肝硬化组高于慢性肝炎组,差异有统计学意义(P均<0.05)。联合检验的灵敏度96.66%、特异度91.66%和准确度93.33%明显高于AFP检验(81.66%、75.00%、77.22%)和PIVKA-Ⅱ检验(86.66%、82.50%、83.88%),差异有统计学意义(χ^(2)=6.792、11.882、18.318,P均<0.05)。结论原发性肝癌患者的异常凝血酶原Ⅱ和甲胎蛋白水平较高,异常凝血酶原Ⅱ、甲胎蛋白联合检测较单一检测的诊断效能较高,能够提升临床诊断的灵敏度、特异度和准确度。
Objective To analyze the value of abnormal prothrombinⅡ+alpha-fetoprotein combined detection in the diagnosis of primary liver cancer.Methods 180 patients with liver disease treated in the Sixth People's Hospital of Qingdao from January 2021 to October 2022 were purposefully selected as the study objects,including 60 patients with primary hepatic carcinoma(HCC group)and 60 patients with hepatitis(hepatitis group)and 60 patients with cir-rhosis(cirrhosis group).Abnormal prothrombinⅡ(PIVKA-Ⅱ)and alpha fetoprotein(AFP)were detected in all pa-tients.The diagnostic efficiency of AFP test,PIVKA-Ⅱand combined test was analyzed.Results Abnormal prothrom-binⅡand alpha-fetoprotein in HCC group were higher than those in other two groups,and liver cirrhosis group was higher than chronic hepatitis group,the differences were statistically significant(all P<0.05).The sensitivity of the combined test was 96.66%,specificity 91.66%and accuracy 93.33%,which were significantly higher than AFP test(81.66%,75.00%,77.22%)and PIVKA-Ⅱtest(86.66%,82.50%,83.88%),and the difference were statistically sig-nificant(χ^(2)=6.792,11.882,18.318,all P<0.05).Conclusion Abnormal prothrombinⅡand alpha-fetoprotein levels are higher in patients with primary liver cancer,and the combined detection of abnormal prothrombinⅡand alpha-fetoprotein has higher diagnostic efficacy than single detection,which can improve the sensitivity,specificity and accu-racy of clinical diagnosis.
作者
郭娜
孙明忠
苗艳艳
GUO Na;SUN Mingzhong;MIAO Yanyan(Department of Oncology,The Sixth People's Hospital of Qingdao,Qingdao 266000,Shandong,China;Department of HepatologyⅡ,The Sixth People's Hospital of Qingdao,Qingdao 266000,Shandong,China;Department of Geriatrics,The Sixth People's Hospital of Qingdao,Qingdao 266000,Shandong,China)
出处
《系统医学》
2024年第12期171-174,共4页
Systems Medicine
基金
青岛市2020年度医药科研指导计划(2020-WJZD149)。
关键词
异常凝血酶原Ⅱ
甲胎蛋白
原发性肝癌
Abnormal prothrombinⅡ
Alpha-fetoprotein
Primary liver cancer